WHO Model Prescribing Information: Drugs Used in Skin Diseases
(1997; 132 pages) [French] [Spanish] Voir le document au format PDF
Table des matières
Afficher le documentPreface
Afficher le documentIntroduction
Ouvrir ce répertoire et afficher son contenuParasitic infections
Ouvrir ce répertoire et afficher son contenuInsect and arachnid bites and stings
Ouvrir ce répertoire et afficher son contenuSuperficial fungal infections
Ouvrir ce répertoire et afficher son contenuSubcutaneous fungal infections
Ouvrir ce répertoire et afficher son contenuBacterial infections
Ouvrir ce répertoire et afficher son contenuViral infections
Ouvrir ce répertoire et afficher son contenuEczematous diseases
Ouvrir ce répertoire et afficher son contenuScaling diseases
Ouvrir ce répertoire et afficher son contenuPapulosquamous diseases
Afficher le documentCutaneous reactions to drugs
Ouvrir ce répertoire et afficher son contenuPigmentary disorders
Ouvrir ce répertoire et afficher son contenuPremalignant lesions and malignant tumours
Ouvrir ce répertoire et afficher son contenuPhotodermatoses
Ouvrir ce répertoire et afficher son contenuBullous dermatoses
Afficher le documentAlopecia areata
Afficher le documentUrticaria
Ouvrir ce répertoire et afficher son contenuConditions common in children
Afficher le documentAcne vulgaris
Afficher le documentPruritus
Afficher le documentTropical ulcers
Ouvrir ce répertoire et afficher son contenuAntimicrobial drugs
Ouvrir ce répertoire et afficher son contenuAntifugal drugs
Ouvrir ce répertoire et afficher son contenuAntiseptic agents
Ouvrir ce répertoire et afficher son contenuKeratoplastic and keratolytic agents
Fermer ce répertoireScabicides and pediculicides
Afficher le documentBenzyl benzoate
Afficher le documentLindane
Afficher le documentPermethrin
Ouvrir ce répertoire et afficher son contenuAnti-inflammatory and antipruritic drugs1
Ouvrir ce répertoire et afficher son contenuAntiallergics and drugs used in anaphylaxis
Ouvrir ce répertoire et afficher son contenuUltraviolet radiation-blocking agents (sunscreens)
Ouvrir ce répertoire et afficher son contenuMiscellaneous drugs
Ouvrir ce répertoire et afficher son contenuAnnex
Afficher le documentSelected WHO Publications of Related Interest
Afficher le documentBack cover
 

Permethrin

Cream, 5%

General information

Permethrin is a topical scabicidal agent for the treatment of infestations with Sarcoptes scabiei, Pediculus humanus capitis and P. humanus corporis. It acts on the nerve cell membranes of the parasites with consequent paralysis. It is more expensive than lindane and benzyl benzoate.

Absorption of permethrin is negligible following topical application.

Clinical information

Uses

Treatment of scabies and pediculosis of the scalp and body.

Dosage and administration

All doses are suitable for adults and children.

Scabies and Pediculus humanus corporis:

The cream should be massaged thoroughly into all skin surfaces, from the scalp to the soles of the feet, and left for at least 8 hours before rinsing. In general, 30 g is sufficient for an average adult. A single application is usually curative.

Pediculus humanus capitis:

The cream should be massaged into damp hair and left for 10 minutes before rinsing.

Household contacts should be treated at the same time. All combs and brushes should be soaked in a pediculicidal solution (see Parasitic infections - Prevention and management) for at least 2 hours.

Contraindication

Known hypersensitivity to synthetic pyrethroids or pyrethrins.

Use in pregnancy

Safe use in pregnancy has not been demonstrated. However, since absorption is negligible, it may be used if necessary.

Precautions

Pruritus, oedema and erythema may be exacerbated.

Adverse effects

Mild and transient burning and stinging sensations may occur after treatment, particularly in cases with severe infestation.

Storage

Cream should be stored in well-closed containers, below 25 °C.

 

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 24 avril 2012